Answers are grounded in this paper and cite their sources.
RATIONALE: Improved understanding and treatment of cystic fibrosis (CF) has led to longer life expectancy, which is accompanied by an increasingly complex regimen of treatments. Suboptimal adherence to the treatment plan, in the context of respiratory disease, is associated with poorer health outcomes. With digital technology being more accessible, it can be used to monitor adherence to inhaled therapies via chipped nebulisers, mobile phone applications and web-based platforms. This technology can allow monitoring of adherence, as well as clinical outcomes, and allow feedback to both the person with CF and their healthcare team. OBJECTIVES: To assess the effects of using digital technology to monitor adherence to inhaled therapies and health status in adults and children with CF. SEARCH METHODS: We searched the Cochrane CF Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched Embase and three clinical trial registries, and checked the references of included studies. The date of last search was 27 February 2025. ELIGIBILITY CRITERIA: We searched for randomised controlled trials (RCTs) looking at the effects of digital technology for monitoring adherence to inhaled therapies of children and adults with CF. OUTCOMES: ). We assessed the number of pulmonary exacerbations by the end of each study. RISK OF BIAS: Using Cochrane's Risk of Bias 2 tool, we assessed the risk of bias within each of the included trials and for each outcome from the randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome and selection of the reported result. SYNTHESIS METHODS: Two review authors screened the search results for studies eligible for inclusion in the review and extracted their data. Due to the difference in the studies' interventions, we analysed the data separately. We assessed the overall certainty of the evidence using GRADE. INCLUDED STUDIES: We included two studies with 628 participants aged five to 41 years. There was one study in each of two different comparisons. RESULTS: % predicted (MD 3.70%, 95% CI -0.23 to 7.63; 1 study, 556 participants; low-certainty evidence). There is probably little or no difference in the incidence of pulmonary exacerbations or QoL between the two groups. We downgraded the certainty of the evidence for indirectness as the intervention was only assessed in an adult population and therefore may not apply to children. AUTHORS' CONCLUSIONS: Digital monitoring plus tailored support via an online platform probably improves adherence to inhaled therapies and reduces treatment burden (but without a corresponding change in QoL) in the medium term (low- and moderate-certainty evidence). In a shorter timeframe, technological enhancement of inhaling antibiotics may improve adherence to treatment (low-certainty evidence). There may be little or no effect on lung function with either intervention, and online monitoring probably makes no difference to pulmonary exacerbations. Future research should assess the effect of digital technology on adherence to inhaled therapies in both children and adults. Consideration of adherence to the total treatment regimen is also important, as improved adherence to inhaled therapies could come at the cost of adherence to other parts of the treatment regimen. FUNDING: The original review was supported by Cochrane Infrastructure funding from the National Institute for Health Research (NIHR). The review was updated with Cochrane CF funding from the CF Foundation and the UK CF Trust. REGISTRATION: Protocol (2020) DOI: 10.1002/14651858.CD013733 Original review (2023) DOI: 10.1002/14651858.CD013733.pub2.
No takes yet. Share an insight, caveat, or question.
Calthorpe et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: